Clinical trials: Rejection
Kidney Transplant, Kidney Transplant Recipient
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of…
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Trial name
- NCT00307125
- Testing
- Rituximab plus immunosuppression
- Where
- 17 sites in United States
- Volunteers
- 757 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion…
- Trial name
- NCT00170885
- Testing
- Everolimus
- Where
- Switzerland
- Sponsor
- Novartis
Kidney Transplantation, Renal Transplantation
A Study to Evaluate FK778 in Kidney Transplant Patients
A dose finding study to evaluate the safety and effectiveness of FK778 in kidney transplant patients
- Conditions
- Kidney Transplantation, Renal Transplantation, Transplantation, Renal, Transplantation, Kidney
- Trial name
- NCT00189735
- Testing
- FK778
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 364 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplant Rejection
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
The purpose of this study is to evaluate the safety of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft…
- Trial name
- CarBel (NCT06918990)
- Testing
- Carfilzomib, Belatacept
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant
Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Concentrations and Outcomes in Thai Transplant Recipients
Tacrolimus is a drug used commonly in kidney transplant patients to prevent graft rejection. Tacrolimus acts in a very narrow range in the blood for its optimum activity.
- Trial name
- NCT02377791
- Testing
- SNP: CYP3A5 gene polymorphisms
- Volunteers
- 170 people
- Sponsor
- Mahidol University
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase II trial studies the side effects and best dose of total-body irradiation when given together with fludarabine phosphate followed by a donor peripheral stem cell transplant in treating patients with myelodysplastic…
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia
- Trial name
- NCT00397813
- Testing
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Kidney Transplant Rejection
The TOGETHER Project - Kidney
Researchers are trying to develop a way to customize immunosuppression treatment, based on the results of a blood test that measures the risk of rejection.
- Trial name
- TOGETHER (NCT03873623)
- Where
- 3 sites in United States
- Volunteers
- 250 people
- Sponsor
- Mayo Clinic
Kidney Transplantation
Rituximab for Pediatric Renal Transplant Rejection
Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University
- Trial name
- NCT00697996
- Testing
- Rituximab for transplant rejection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Antibody Mediated Rejection of Kidney Transplant
C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an…
- Trial name
- NCT02936479
- Testing
- C1-INH (Berinert)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- NYU Langone Health
Liver Transplant Rejection, Immune System Suppression
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
Prograf and Envarsus are two different formulations of Tacrolimus which is used as an immunosuppressant in liver transplant (LT) patients.
- Trial name
- NCT05655273
- Testing
- Prograf, Envarsus
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Heart Transplant Rejection
The TOGETHER Project - Heart
The researchers are trying to develop a way to measure the risk of transplant rejection with a blood test.
- Trial name
- TOGETHER (NCT03833050)
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Mayo Clinic
Heart Transplant Rejection, Heart Transplant Infection
TTV Viral Load in Heart Transplant Recipients
This prospective, multicenter, non-interventional trial aims to study the association between TTV viral load and the occurrence of rejection or infection during the first year after transplantation.
- Conditions
- Heart Transplant Rejection, Heart Transplant Infection, Virus
- Trial name
- TTVCoeur (NCT05064462)
- Testing
- Collection of EDTA blood sample (5 to 7 ml)
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Rejection of Renal Transplant
Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation
The primary objective of this study is to determine whether 4 grams daily of mycophenolate mofetil (MMF) results in a greater proportion of individuals adequately exposed as measured by drug levels (area under the curve of > 40…
- Trial name
- NCT00943228
- Testing
- mycophenolate mofetil
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Nova Scotia Health Authority
Transplant;Failure,Kidney, Kidney Transplant Rejection
Impact of Microvascular Inflammation on Kidney Allograft Outcome
Graft microvascular inflammation poses a significant challenge to successful kidney transplantation due to its heterogeneous clinical presentation.
- Trial name
- NCT06496269
- Testing
- No intervention
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 6,000 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Transplant; Failure, Kidney
Pilot Study of Contrast-Enhanced Ultrasound of Transplanted Kidney
To check the possibility of the acquisition of a number of parameters through real-time contrast-enhanced ultrasound and sonoelastography images and to verify the correlation with pathologic results from ultrasound guided biopsy…
- Trial name
- NCT01883583
- Testing
- Contrast-enhanced Ultrasound And Sonoelastography
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Seoul National University Hospital
Implant or Graft; Rejection
Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
The main purpose of this study is to find out whether treatment to prevent kidney rejection with belatacept in presence of Thymoglobulin induction and withdrawal of steroids will result in less delayed graft function or "sleepy…
- Trial name
- NCT02152345
- Testing
- Belatacept, Tacrolimus, Mycophenolate
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Columbia University
Hematologic Malignancy, Bone Marrow Transplant Rejection
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor…
- Conditions
- Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT06398457
- Testing
- Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Late Rejection of Renal Transplant, Antibody-mediated Rejection
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
Late antibody-mediated rejection (AMR) after kidney transplantation is defined as a separate rejection entity. So far, no appropriate treatment has been established for this rejection type.
- Trial name
- BORTEJECT (NCT01873157)
- Testing
- Bortezomib
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- Medical University of Vienna
Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients
This investigator-initiated post-marketing study will evaluate the role of Hispanic ethnicity on drug dosing of Envarsus in first-time stable renal transplant recipients.
- Trial name
- NCT03438773
- Testing
- Envarsus, Tacrolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- California Institute of Renal Research
Liver Transplantation, Graft Versus Host Disease
The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
The aim of this research is to design a randomized controlled clinical study, which is based on HLA matching rate to guide tacrolimus regimen.
- Conditions
- Liver Transplantation, Graft Versus Host Disease, Graft Rejection, Drug-Related Side Effects and Adverse Reactions
- Trial name
- NCT03147157
- Testing
- tacrolimus regimen guided by HLA matching rate
- Volunteers
- 120 people
- Sponsor
- The First Hospital of Jilin University